Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine loaded with tumor lysate
- Development stage
- Unknown
- Lead developer
- Instituto Oncológico Dr Rosell
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Autologous dendritic cell vaccine loaded with tumor lysate is a personalized cancer immunotherapy developed by the Instituto Oncologico Dr. Rosell. The vaccine is produced by harvesting a patient's own dendritic cells and 'pulsing' or loading them with a lysate derived from the patient's own tumor tissue. This process allows the dendritic cells to present a diverse set of tumor-associated antigens (TAAs) to the patient's immune system. Once re-administered, these mature, antigen-presenting cells activate T-lymphocytes to recognize and destroy tumor cells expressing those specific antigens. It is currently being investigated in Phase Ib/II clinical trials as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) in combination with the PD-L1 inhibitor atezolizumab.
- Other names
- autologous tumor lysate-pulsed dendritic cell vaccinetumor lysate-loaded dendritic cell vaccine
02
Targets
Patient-specific tumor-derived antigens contained in the autologous tumor lysate
Beyond the preview
Go deeper on autologous dendritic cell vaccine loaded with tumor lysate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine loaded with tumor lysate.